Evotec Receives $10M Milestone From Bristol Myers Squibb As BMS-986506 Molecular Glue Enters Phase 1 Trial For Clear Cell Renal Cell Carcinoma

Evotec has received a $10 million milestone payment from Bristol Myers Squibb (BMS) as the BMS-986506 molecular glue enters Phase 1 trials for advanced clear cell renal cell carcinoma. This marks a significant step in their collaboration, aiming to create new treatment options for this common form of kidney cancer. The trial initiation underscores the advancement of Evotec's oncology platform and its capabilities in multi-omics screening and AI-supported drug design.